These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20526296)

  • 21. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapy: An immune one-two punch.
    Bourzac K
    Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

  • 24. What Nurses and Patients Need to Know About Sipulecucel-T Immunotherapy for Prostate Cancer.
    Becze E
    ONS Connect; 2015 Jun; 30(2):40-1. PubMed ID: 26146750
    [No Abstract]   [Full Text] [Related]  

  • 25. Immune-boosting prostate cancer vaccine endorsed by FDA advisors.
    McBride D
    ONS Connect; 2007 Jul; 22(7):19. PubMed ID: 17694780
    [No Abstract]   [Full Text] [Related]  

  • 26. Searching for the ideal cancer vaccine.
    Cancer Biol Ther; 2009 Jan; 8(2):104-5. PubMed ID: 19263513
    [No Abstract]   [Full Text] [Related]  

  • 27. Citizenship in our profession.
    Droller MJ
    J Urol; 2010 Oct; 184(4):1248-50. PubMed ID: 20723933
    [No Abstract]   [Full Text] [Related]  

  • 28. Continuous improvement versus innovation: the case for sipuleucel-T.
    Tombal B
    Eur Urol; 2012 Apr; 61(4):648-9; discussion 650-1. PubMed ID: 22154024
    [No Abstract]   [Full Text] [Related]  

  • 29. Approval of provenge seen as first step for cancer treatment vaccines.
    Brower V
    J Natl Cancer Inst; 2010 Aug; 102(15):1108-10. PubMed ID: 20668267
    [No Abstract]   [Full Text] [Related]  

  • 30. Is Provenge Angst a symbol or symptom of the times?
    Holcombe DG
    Am J Manag Care; 2012 May; 18(3 Spec No.):SP108-9. PubMed ID: 22642274
    [No Abstract]   [Full Text] [Related]  

  • 31. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer.
    McKarney I
    Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What happened to the Provenge (Sipuleucel-T) vaccine for hormone refractory prostate cancer?
    Moyad MA
    Urol Nurs; 2007 Jun; 27(3):256-7. PubMed ID: 17674606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate cancer treatment: the times they are a' changin'.
    Kirby R; Challacombe B; Dasgupta P; Fitzpatrick JM
    BJU Int; 2012 Nov; 110(10):1408-11. PubMed ID: 22937730
    [No Abstract]   [Full Text] [Related]  

  • 34. Cancer immunotherapy.
    White RL; Amin A
    Surg Oncol Clin N Am; 2011 Jul; 20(3):531-54, ix. PubMed ID: 21640920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dendritic cell vaccine hits FDA roadblock.
    Morrow T
    Manag Care; 2007 Jun; 16(6):52-3. PubMed ID: 17682740
    [No Abstract]   [Full Text] [Related]  

  • 36. Cancer Vaccines.
    DeMaria PJ; Bilusic M
    Hematol Oncol Clin North Am; 2019 Apr; 33(2):199-214. PubMed ID: 30832995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Provenge approval means sensitive coverage decisions.
    Silverman E
    Manag Care; 2010 Sep; 19(9):31-4. PubMed ID: 20931888
    [No Abstract]   [Full Text] [Related]  

  • 38. Another cancer vaccine, another retreat.
    Dalzell MD
    Manag Care; 2013 Feb; 22(2):27-8. PubMed ID: 23451534
    [No Abstract]   [Full Text] [Related]  

  • 39. An empiric victory.
    Nat Biotechnol; 2010 Jun; 28(6):529. PubMed ID: 20531311
    [No Abstract]   [Full Text] [Related]  

  • 40. David Urdal. Interview with Asher Mullard.
    Nat Rev Drug Discov; 2011 Oct; 10(11):806-7. PubMed ID: 22037031
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.